Branded Legacy Inc Stock Price, News & Analysis

Branded Legacy (OTC: BLEG) has signed a Letter of Intent to acquire Bio-Legacy Evaluative Group for $1.5 million in Preferred D stock. The acquisition targets the intranasal drug delivery market, specifically focusing on naloxone and vaccine delivery technologies.

Key terms include a two-year holding period for the Preferred D stock, convertible upon achieving a $40 million post-acquisition valuation. The company commits $1 million for R&D upon OTCQB uplisting and reaching $0.01/share. The transaction is expected to close within 14 days.

Post-acquisition, Bio-Legacy's CEO Amin Janmohamed will become CEO and Chairman of Branded Legacy. The company projects potential revenues of $183.3 million by Year 5, with manufacturing prototyping in Q3 2025, clinical trials in 2026, and market readiness by Q1 2027.

Branded Legacy Inc. (OTC: BLEG) announced a major leadership transition and pending merger with an innovative addiction therapeutics company. The entire existing management team has resigned, with Jeffery Robison appointed as Interim CEO. A Letter of Intent is expected to be executed this week, with merger completion anticipated within two weeks.

The target company specializes in advanced intranasal drug delivery systems, particularly for Naloxone, featuring a patented all-in-one device that reduces costs and improves treatment consistency. Their technology platform includes a second device enabling point-of-care reconstitution of medications, expanding into vaccines and cold chain-dependent therapeutics.

The merged entity projects $40 million in first-year revenue. The global addiction treatment market is expected to grow from $9 billion in 2023 to $16.7 billion by 2033, with the naloxone market projected to reach $2.48 billion by 2032.

Branded Legacy (OTC.PK: BLEG) faces significant challenges including a cyber attack by former employees that disrupted operations and reduced projected revenue from a $10M contract. The company has restructured by releasing several subsidiaries and is now focusing on its Sycamore BioPharma division.

The company plans to sell MariJ Pharmaceuticals to offset dilution and will increase authorized shares to fund operations. BLEG is in discussions to supply one-fifth of Europe's CBD market, targeting production of 3 tons of CBD isolate monthly. The company is also rebranding to Royal Enterprises.

Branded Legacy, Inc. (OTC.PK: BLEG) has secured a significant client, Monster Group, Inc., with $70,000,000 in annual revenue. This partnership is expected to boost Branded Legacy's revenue to over $10,000,000 annually by 2025. The company's subsidiary, Sycamore BioPharma, will provide high-quality mitragynine salt for the client's product lines sold across the Middle East, Europe, and North America.

The current supply line is generating approximately $60,000 weekly for Branded Legacy, with a 500% growth target set for the next six months. The company plans to take over lab operations for this client within 6 to 10 months. Additionally, Branded Legacy's subsidiary Royal Biotek is in negotiations with a large distributor for Delta 8 and Delta 9 distillate, potentially leading to similar revenue figures.

CEO Dave Oswald stated that this development positions Branded Legacy to be self-funded moving forward, reducing the need for additional funding. The company is also in talks with several potential acquisition candidates to complement its existing operations and strategic growth plans.

Fifty 1 Labs and All-In-Extracts have entered a joint venture to develop a new testosterone-boosting supplement. Combining Fifty 1 Labs' supplement expertise and All-In-Extracts' advanced botanical extraction methods, they aim to create a product that supports natural testosterone production and overall well-being.

Clinical trials will begin promptly to ensure safety, efficacy, and quality, with the product expected to launch in Q4 2024 initially in the U.S., followed by international expansion. The supplement targets common issues such as low energy and reduced muscle mass and is intended for both men and women.

Both companies emphasize transparency, safety, and quality, with plans for an extensive marketing campaign to educate consumers.

Branded Legacy (OTC.PK: BLEG) has announced an exclusive extraction agreement with Botany Evolution, a leading kava distributor. This partnership is expected to generate over $1.25 million in annual profits. Royal Biotek will produce kava extracts, including a 30% kava extract and a 70% kavalactone paste. Botany Evolution will provide all necessary kava inputs. This agreement aims to meet the growing demand for kava in wellness and recreational markets. The companies plan to explore further projects, including white-label gummies and beverages.

Branded Legacy (OTCPK: BLEG), a leading wellness and skincare provider, has announced a collaboration with renowned celebrity tattoo artist Kat Tat. This partnership has resulted in the creation of Enigma by Kat Tat, a premium shea butter-based tattoo aftercare product aimed at enhancing and preserving the beauty of fresh tattoos. Kat Tat, known for her appearances on VH1's 'Black Ink Crew: Chicago,' brings her extensive industry experience to the formulation of the product. Enigma by Kat Tat is expected to boost Branded Legacy's product portfolio and brand visibility, leveraging Kat Tat's celebrity status to increase consumer interest and shareholder value. The product will soon be available for purchase online and at select retailers nationwide.

Branded Legacy (OTCQB: BLEG), a leading wellness product provider, invites shareholders to an exclusive open house on June 14th to celebrate the new extraction and manufacturing equipment. The company announced a share buyback initiative and pledged to maintain the current authorized share count, avoiding reverse splits unless necessary for uplisting. Additionally, Branded Legacy introduced the Royal Biotek Kava Vape, receiving strong distributor feedback and pre-sales. The company reported a net income of $3.8M for 2023, boosted by the retirement of over 2.4 billion shares, and has signed multiple white label contracts for 2024.

Summary not available.